Drrx stock zacks

DRRX | Complete Durect Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Many of the stocks listed here are easily subjected to manipulation DRRX (T /$3) Durect Corp. technology right now is in COPD (Cronic Obstructive Pulmonary Disease). http://ir.pulmatrix.com/Zacks-Initiates-on-Pulmatrix- NASDAQ-PULM

View DURECT Corporation DRRX investment & stock information. Get the latest DURECT Corporation DRRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. DURECT Corporation (DRRX) Stock Price, Quote, History ... Find the latest DURECT Corporation (DRRX) stock quote, history, news and other vital information to help you with your stock trading and investing. DRRX Stock Price, Forecast & News (DURECT) | MarketBeat Researching DURECT (NASDAQ:DRRX) stock? View DRRX's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Fundamental company data provided by Morningstar and Zacks Investment Research. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or DRRX Stock Price | Durect Corp. Stock Quote ... - MarketWatch

Get breaking news and analysis on Endeavour Silver Corp. (EXK) stock, price quote and chart, trading and investing tools. Sign in Marketplace Subscribe. at Zacks.com (Feb 24, 2020)

This value represents a 40.00% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2016 Price to Earnings ratio for DRRX is -3.88 vs. an industry ratio of 5.60. Durect Corp DRRX - Quotes, Financials, News, Charts and ... Durect Corp DRRX Overview. About Durect Corp Analysts' recommendations provided by ZACKS Investment Research, Inc. Analysts' recommendations are for informational purposes only. DRRX | Durect Corp Financial Vitals | US News Best Stocks Financial summary and company information for Durect Corp DRRX Analysts' recommendations provided by ZACKS Investment There's seemingly a dramatic gulf between economic numbers and …

By Grant Zeng, CFA NASDAQ:DRRX On August 1, Durect (NASDAQ:DRRX) announced its financial results for the second quarter of 2016 ended June 30. Total revenues for 2Q16 were $3.2 million, compared to $4.4 million for the same period of last year, a decrease of 28.8%. RD expenses for 2Q16 were $7.9 million, compared to $5.6 million for 2Q15.

DURECT Corporation (DRRX) Stock Analysis & News | Seeking ... Get breaking news and analysis on DURECT Corporation (DRRX) stock, price quote and chart, trading and investing tools. Sign in Marketplace Subscribe. Premium at Zacks.com (Jun 28, 2018)

What Awaits ASMB, DRRX, EIGR At The Liver Meeting ...

Zacks Small Cap Research - DRRX: Update on Second Quarter ... By Grant Zeng, CFA NASDAQ:DRRX On August 1, Durect (NASDAQ:DRRX) announced its financial results for the second quarter of 2016 ended June 30. Total revenues for 2Q16 were $3.2 million, compared to $4.4 million for the same period of last year, a decrease of 28.8%. RD expenses for 2Q16 were $7.9 million, compared to $5.6 million for 2Q15. DRRX DURECT Corporation Stock Quote - FINVIZ.com

DRRX: DURECT Corporation - Earnings Announcements. Stay up to date with lastest Earnings Announcements for DURECT Corporation from Zacks Investment 

DRRX: DURECT Corporation broker recommendation chart. Get the latest chart with broker recommendations from Zacks Investment Research. DRRX: DURECT Corporation - Earnings Announcements. Stay up to date with lastest Earnings Announcements for DURECT Corporation from Zacks Investment  DRRX DURECT Corporation daily Stock Chart Opportunities Make DRRX Particularly Attractive at Current Valuation Zacks Small Cap Research. Aug-01- 19  According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.04. The reported EPS for the same   Researching DURECT (NASDAQ:DRRX) stock? View DRRX's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at  Market Data and Calendars. Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, 

Zacks Investment Research Page 3 scr.zacks.com 150mg severe cohort (n=4) is now enrolling. This is the final group of severe patients, following completion of which is expected to be followed by DRRX meeting with FDA to discuss details related to a pathway for U.S. regulatory approval o Moderate cohort JCP J. C. Penney Company, Inc. — Stock ... - StockTwits Securities products and services offered to self-directed investors through ST Invest, LLC. Member FINRA / SIPC.ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. Please read important legal disclosures.